News-Medical.Net Pharmaceutical News

Latest Pharmaceutical News and Research

Updated: 10 hours 4 min ago

Clinuvel submits SCENESSE MAA to EMA for treatment of erythropoietic protoporphyria

13 hours 49 min ago

Clinuvel Pharmaceuticals Limited today announced that it has submitted a marketing authorisation application (MAA) for its first-in-class drug SCENESSE (afamelanotide 16mg implant) to the European Medicines Agency.

Categories: News

All material found on the BC Drug and Poison Information Centre (DPIC) website is provided for informational purposes only. It is not meant to replace the expert advice of a healthcare professional such as a physician, pharmacist, nurse or qualified poison specialist. Use of this site is governed and restricted by specific terms of use. Please review the terms and conditions prior to using the DPIC website. In the event of a poisoning emergency, call your local poison control centre immediately. Portions of this web site are intended for healthcare professionals. Interpretation and application of information may require more detailed explanation than contained herein, particularly regarding any clinical information that is found in or linked to this site. Patients are advised to consult their health care provider regarding diagnosis and treatment, and for assistance in interpreting these materials and applying them in individual cases.

British Columbia Drug and Poison Information Centre (BC DPIC)

Poison Information

Drug Information

Publications

Clinuvel submits SCENESSE MAA to EMA for treatment of erythropoietic protoporphyria

Follow DPIC